TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomised, Multicenter, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for the Secondary Prevention of Venous Thromboembolism.
Brief Summary: The general aim of this study is to determine the comparative safety and efficacy of dabigatran etexilate administered orally and warfarin (International Normalized Ratio (INR) of 2.0-3.0) for the long-term treatment and secondary prevention of symptomatic venous thromboembolism in patients who have been successfully treated with standard doses of an approved anticoagulant for three to twelve months for confirmed acute symptomatic Venous Thrombo-embolism.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
B: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin, Drug: warfarin, Drug: Placebo for apixaban | Arm Label: Enoxaparin + Warfarin; Type: EXPERIMENTAL; Interventions: Drug: Placebo for enoxaparin, Drug: Placebo for warfarin, Drug: apixaban | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo for apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo for enoxaparin; Assigned to Arm(s): Enoxaparin + Warfarin | Intervention Type: DRUG; Name: Placebo for warfarin; Assigned to Arm(s): Enoxaparin + Warfarin | Intervention Type: DRUG; Name: apixaban; Assigned to Arm(s): Enoxaparin + Warfarin
C: Arm Label: Dabigatran; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran | Arm Label: Warfarin (INR of 2.0-3.0); Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Dabigatran; Assigned to Arm(s): Dabigatran | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin (INR of 2.0-3.0)
D: Arm Label: Apixaban; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Dalteparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dalteparin | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Dalteparin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomised, Multicenter, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for the Secondary Prevention of Venous Thromboembolism.
Brief Summary: The general aim of this study is to determine the comparative safety and efficacy of dabigatran etexilate administered orally and warfarin (International Normalized Ratio (INR) of 2.0-3.0) for the long-term treatment and secondary prevention of symptomatic venous thromboembolism in patients who have been successfully treated with standard doses of an approved anticoagulant for three to twelve months for confirmed acute symptomatic Venous Thrombo-embolism.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated heparin | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Arm 3
B: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin overlapping with and followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin overlapping with and followed by VKA; Assigned to Arm(s): Enoxaparin/VKA
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BAY 59-7939 | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: BAY 59-7939 | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: ASA | Intervention Type: DRUG; Name: BAY 59-7939; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: BAY 59-7939; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: ASA; Assigned to Arm(s): Arm 3
D: Arm Label: Dabigatran; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran | Arm Label: Warfarin (INR of 2.0-3.0); Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Dabigatran; Assigned to Arm(s): Dabigatran | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin (INR of 2.0-3.0)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomised, Multicenter, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for the Secondary Prevention of Venous Thromboembolism.
Brief Summary: The general aim of this study is to determine the comparative safety and efficacy of dabigatran etexilate administered orally and warfarin (International Normalized Ratio (INR) of 2.0-3.0) for the long-term treatment and secondary prevention of symptomatic venous thromboembolism in patients who have been successfully treated with standard doses of an approved anticoagulant for three to twelve months for confirmed acute symptomatic Venous Thrombo-embolism.


Options:
A: Arm Label: GFFC + LMWH; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparine | Intervention Type: DRUG; Name: Enoxaparine; Assigned to Arm(s): GFFC + LMWH
B: Arm Label: heparin/edoxaban tosylate; Type: EXPERIMENTAL; Interventions: Drug: edoxaban tosylate(DU-176b), Drug: low molecular weight heparin/unfractionated heparin | Arm Label: heparin/warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin/unfractionated heparin, Drug: warfarin | Intervention Type: DRUG; Name: edoxaban tosylate(DU-176b); Assigned to Arm(s): heparin/edoxaban tosylate | Intervention Type: DRUG; Name: low molecular weight heparin/unfractionated heparin; Assigned to Arm(s): heparin/edoxaban tosylate, heparin/warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): heparin/warfarin
C: Arm Label: High Risk for VTE recieving dalteparin; Type: EXPERIMENTAL; Interventions: Drug: dalteparin injection | Arm Label: High Risk for VTE No therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Risk for VTE; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: dalteparin injection; Assigned to Arm(s): High Risk for VTE recieving dalteparin
D: Arm Label: Dabigatran; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran | Arm Label: Warfarin (INR of 2.0-3.0); Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Dabigatran; Assigned to Arm(s): Dabigatran | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin (INR of 2.0-3.0)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomised, Multicenter, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for the Secondary Prevention of Venous Thromboembolism.
Brief Summary: The general aim of this study is to determine the comparative safety and efficacy of dabigatran etexilate administered orally and warfarin (International Normalized Ratio (INR) of 2.0-3.0) for the long-term treatment and secondary prevention of symptomatic venous thromboembolism in patients who have been successfully treated with standard doses of an approved anticoagulant for three to twelve months for confirmed acute symptomatic Venous Thrombo-embolism.


Options:
A: Arm Label: Certoparin; Type: EXPERIMENTAL; Interventions: Drug: Certoparin | Arm Label: Unfractionated Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated Heparin | Intervention Type: DRUG; Name: Certoparin; Assigned to Arm(s): Certoparin | Intervention Type: DRUG; Name: Unfractionated Heparin; Assigned to Arm(s): Unfractionated Heparin
B: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin followed by VKA; Assigned to Arm(s): Enoxaparin/VKA
C: Arm Label: Innohep®; Type: EXPERIMENTAL; Interventions: Drug: Innohep® | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Innohep®; Assigned to Arm(s): Innohep®
D: Arm Label: Dabigatran; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran | Arm Label: Warfarin (INR of 2.0-3.0); Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Dabigatran; Assigned to Arm(s): Dabigatran | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin (INR of 2.0-3.0)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Single Migraine Attack, Placebo-controlled, Parallel-group Multicenter Study to Evaluate the Efficacy and Tolerability of Trexima (Sumatriptan Succinate.Naproxen Sodium) Tablets vs Placebo When Administered During the Mild Pain Phase of Menstrual Migraine in Women With Dysmenorrhea
Brief Summary: This study was designed to determine efficacy of TREXIMET (sumatriptan/naproxen sodium), formerly known as TREXIMA compared to placebo for the treatment of a menstrual migraine.


Options:
A: Arm Label: arm 1; Type: EXPERIMENTAL; Interventions: Drug: sumatriptan succinate/naproxen sodium | Arm Label: arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: sumatriptan succinate/naproxen sodium; Assigned to Arm(s): arm 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): arm 2
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Treximet | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Migraine rescue medication of choice | Intervention Type: DRUG; Name: Treximet; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Migraine rescue medication of choice; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: sumatriptan succinate/naproxen sodium; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: sumatriptan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: naproxen sodium; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Use of Desirudin Versus Heparin for Thrombosis Prophylaxis in Cardiothoracic Surgery Patients
Brief Summary: A blood clot in the veins, also known as deep venous thrombosis (DVT), is one of the most common complications after surgery. This may result in death if a clot breaks off and travel to the lungs; this is referred to as pulmonary embolism (PE). After heart surgery the incidence of DVT ranges from 20-48% and following lung surgery the incidence is 19-26%. In order to decrease the likelihood of this complication, patients receive by injection a blood thinning medicine. Heparin is the usual medicine used for this purpose following heart and lung surgery. Recently there have been reports that other medicines may be more effective than heparin for this purpose. Also there have been reports that some patients develop antibodies to heparin. When this occurs, this may prevent the heparin from being effective and may even promote the formation of blood clots. Antibodies to heparin may be present more often following heart and lung surgery than other types of surgery. There is a new medicine called desirudin (Iprivask), which may be used instead of heparin to prevent blood clots following heart and lung surgery. Desirudin is currently approved by the FDA to prevent blood clots following hip surgery. The purpose of this study is to compare desirudin with heparin for the prevention of vein clots after heart and lung surgery.


Options:
A: Arm Label: Antithrombin III treatment group; Type: EXPERIMENTAL; Interventions: Drug: Antithrombin III | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Antithrombin III; Assigned to Arm(s): Antithrombin III treatment group
B: Arm Label: Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin | Arm Label: Desirudin (Iprivask™); Type: EXPERIMENTAL; Interventions: Drug: Desirudin (Iprivask™) | Intervention Type: DRUG; Name: Desirudin (Iprivask™); Assigned to Arm(s): Desirudin (Iprivask™) | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): Heparin
C: Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Warfarin vs ASA; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Single Migraine Attack, Placebo -Controlled, Patallel-group Multicenter Study to Evaluate the Efficacy and Tolerability or Trexima (Sumatriptan Succinate/Naproxen Sodium) Tablets vs Placebo When Administered During the Mild Pain Phase of Menstrual Migraine in Women With Dysmenorrhea
Brief Summary: This study was designed to determine efficacy of TREXIMA compared to placebo for the treatment of a menstrual migraine.


Options:
A: Arm Label: arm 1; Type: EXPERIMENTAL; Interventions: Drug: sumatriptan succinate/naproxen sodium | Arm Label: arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: sumatriptan succinate/naproxen sodium; Assigned to Arm(s): arm 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): arm 2
B: Intervention Type: DRUG; Name: sumatriptan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: naproxen sodium; Assigned to Arm(s): N/A
C: Arm Label: TPB; Type: OTHER; Interventions: Drug: TREXIMET®, Drug: Butalbital-containing Combination Medications (BCM), Drug: placebo | Arm Label: TBP; Type: OTHER; Interventions: Drug: TREXIMET®, Drug: Butalbital-containing Combination Medications (BCM), Drug: placebo | Arm Label: BTP; Type: OTHER; Interventions: Drug: TREXIMET®, Drug: Butalbital-containing Combination Medications (BCM), Drug: placebo | Arm Label: BPT; Type: OTHER; Interventions: Drug: TREXIMET®, Drug: Butalbital-containing Combination Medications (BCM), Drug: placebo | Arm Label: PTB; Type: OTHER; Interventions: Drug: TREXIMET®, Drug: Butalbital-containing Combination Medications (BCM), Drug: placebo | Arm Label: PBT; Type: OTHER; Interventions: Drug: TREXIMET®, Drug: Butalbital-containing Combination Medications (BCM), Drug: placebo | Intervention Type: DRUG; Name: TREXIMET®; Assigned to Arm(s): BPT, BTP, PBT, PTB, TBP, TPB | Intervention Type: DRUG; Name: Butalbital-containing Combination Medications (BCM); Assigned to Arm(s): BPT, BTP, PBT, PTB, TBP, TPB | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): BPT, BTP, PBT, PTB, TBP, TPB
D: Intervention Type: DRUG; Name: sumatriptan succinate/naproxen sodium; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RECORD 1 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE, Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
Brief Summary: The purpose of this study is to assess if 10 mg BAY 59-7939, taken once daily as a tablet, is safe and prevent blood clot which may form after total hip replacement operation.


Options:
A: Arm Label: Experimental group (SCD + GCS + LMWH); Type: EXPERIMENTAL; Interventions: Device: SCD, Device: GCS, Drug: LMWH | Arm Label: Control group (GCS + LMWH); Type: ACTIVE_COMPARATOR; Interventions: Device: GCS, Drug: LMWH | Intervention Type: DEVICE; Name: SCD; Assigned to Arm(s): Experimental group (SCD + GCS + LMWH) | Intervention Type: DEVICE; Name: GCS; Assigned to Arm(s): Control group (GCS + LMWH), Experimental group (SCD + GCS + LMWH) | Intervention Type: DRUG; Name: LMWH; Assigned to Arm(s): Control group (GCS + LMWH), Experimental group (SCD + GCS + LMWH)
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (BAY59-7939) | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Rivaroxaban (BAY59-7939); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Arm 2
C: Arm Label: Intermittent Pneumatic Compression(IPC); Type: EXPERIMENTAL; Interventions: Device: pneumatic compression | Arm Label: No Intermittent Pneumatic Compression; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: pneumatic compression; Assigned to Arm(s): Intermittent Pneumatic Compression(IPC)
D: Arm Label: intermittent pneumatic compression; Type: EXPERIMENTAL; Interventions: Drug: low molecular weight heparin | Intervention Type: DRUG; Name: low molecular weight heparin; Assigned to Arm(s): intermittent pneumatic compression

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RECORD 1 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE, Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
Brief Summary: The purpose of this study is to assess if 10 mg BAY 59-7939, taken once daily as a tablet, is safe and prevent blood clot which may form after total hip replacement operation.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (BAY59-7939) | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Rivaroxaban (BAY59-7939); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Arm 2
B: Arm Label: dabigatran etexilate 75 mg; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate | Arm Label: dabigatran etexilate 110 mg; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate | Arm Label: enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: enoxaparin | Intervention Type: DRUG; Name: dabigatran etexilate; Assigned to Arm(s): dabigatran etexilate 75 mg | Intervention Type: DRUG; Name: dabigatran etexilate; Assigned to Arm(s): dabigatran etexilate 110 mg | Intervention Type: DRUG; Name: enoxaparin; Assigned to Arm(s): enoxaparin
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (BAY59-7939) | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Rivaroxaban (BAY59-7939); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Arm 2
D: Intervention Type: PROCEDURE; Name: Bilateral ultrasound examination 7+/- 2 after surgery; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Parallel Groups, Dose-finding, Placebo-controlled, Multi-centre, Proof of Concept Study Assessing the Effect of 3-wk Treatment With 1 of 3 Oral Doses of Quinagolide & Placebo in Preventing Ovarian Hyperstimulation Syndrome in Women Undergoing Controlled Ovarian Hyperstimulation.
Brief Summary: Women included in this study are undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (ART) and present with signs of moderate risk of developing OHSS.


Options:
A: Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Drug: Control | Arm Label: Cabergoline; Type: EXPERIMENTAL; Interventions: Drug: Cabergoline | Intervention Type: DRUG; Name: Cabergoline; Assigned to Arm(s): Cabergoline | Intervention Type: DRUG; Name: Control; Assigned to Arm(s): Control
B: Arm Label: Coasting; Type: ACTIVE_COMPARATOR; Interventions: Procedure: ICSI | Arm Label: Cabergoline; Type: ACTIVE_COMPARATOR; Interventions: Procedure: ICSI | Arm Label: Coasting and Cabergoline; Type: ACTIVE_COMPARATOR; Interventions: Procedure: ICSI | Intervention Type: PROCEDURE; Name: ICSI; Assigned to Arm(s): Cabergoline, Coasting, Coasting and Cabergoline
C: Arm Label: Cabergoline group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cabergoline | Arm Label: GnRH antagonist rescue & cabergoline group; Type: EXPERIMENTAL; Interventions: Drug: GnRH antagonist rescue & cabergoline | Intervention Type: DRUG; Name: Cabergoline; Assigned to Arm(s): Cabergoline group | Intervention Type: DRUG; Name: GnRH antagonist rescue & cabergoline; Assigned to Arm(s): GnRH antagonist rescue & cabergoline group
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Norprolac | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Norprolac | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Norprolac | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Norprolac | Intervention Type: DRUG; Name: Norprolac; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Norprolac; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Norprolac; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Norprolac; Assigned to Arm(s): 4

Answer: D